Calendario›INO›INO-3107

INO-3107

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Ensayo de INOVIO PHARMACEUTICALS, INC. en Respiratory Papillomatosis (del registro, en inglés).

Fase

Fase 1/2

Estado

Completado

Participantes

32

previstos

Centros

11

Fin del objetivo primario

dic 2022

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en oct 2020.

Qué mide

Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug through 30 days following the last dose (approximately up to Week 13)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a Phase 1/2 open-label, multicenter trial to evaluate the safety, tolerability, immunogenicity, and efficacy of INO-3107 in participants with human papilloma virus type 6 (HPV-6) and/or type 11 (HPV-11)-associated recurrent respiratory papillomatosis (RRP). The trial population will include participants who have been diagnosed with either Juvenile-Onset RRP (J-O RRP) as defined by age at first diagnosis \<12 years or with Adult- Onset RRP (A-O RRP) as defined by age at first diagnosis ≥12 years. A safety run-in will be performed with up to six participants with a one week waiting period between each enrolled participant.

Más ensayos de INO

Todos los de INO, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04398433), actualizada en mar 2026.